

Low seroprevalence of Q fever in The Netherlands prior to a series of large outbreaks

B. SCHIMMER^{1*}, D. W. NOTERMANS¹, M. G. HARMS¹, J. H. J. REIMERINK¹,
J. BAKKER¹, P. SCHNEEBERGER², L. MOLLEMA¹, P. TEUNIS¹, W. VAN PELT¹
AND Y. VAN DUYNHOVEN¹

¹ Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands

² Laboratory for Medical Microbiology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands

(Accepted 19 January 2011; first published online 16 February 2011)

SUMMARY

The Netherlands has experienced large community outbreaks of Q fever since 2007. Sera and questionnaires containing epidemiological data from 5654 individuals were obtained in a nationwide seroprevalence survey used to evaluate the National Immunization Programme in 2006–2007. We tested these sera for IgG phase-2 antibodies against *Coxiella burnetii* with an ELISA to estimate the seroprevalence and to identify determinants for seropositivity before the Q fever outbreaks occurred. Overall seroprevalence was 1·5% [95% confidence interval (CI) 1·3–1·7]. Corrected for confirmation with immunofluorescence results in a subset, the estimated seroprevalence was 2·4%. Seropositivity ranged from 0·48% (95% CI 0·00–0·96) in the 0–4 years age group to 2·30% (95% CI 1·46–3·15) in the 60–79 years age group. Keeping ruminants, increasing age and being born in Turkey were independent risk factors for seropositivity. The low seroprevalence before the start of the outbreaks supports the hypothesis that The Netherlands has been confronted with a newly emerging Q fever problem since spring 2007.

Key words: *Coxiella*, epidemiology, Q fever, risk factors, serology.

INTRODUCTION

Q fever is a worldwide zoonosis caused by *Coxiella burnetii*, a Gram-negative bacterium that can survive for a prolonged time in the environment in a spore-like stage. Until 2007, Q fever was a rarely reported notifiable disease in The Netherlands, with 5–20 cases presenting annually and without seasonal trend. However, underdiagnosis and consequently

underreporting were suspected as very few laboratories consistently tested pneumonia cases for *Coxiella* infection. Q fever emerged in 2007, followed by subsequently larger epidemics in 2008 and 2009 [1, 2], which were probably related to intensive dairy goat farming [3–5]. There is some evidence for a few retrospectively identified clusters of hospital admissions for respiratory illness in 2005 and 2006 that might have been caused by Q fever [6]. A seroprevalence study in the 1980s by Richardus *et al.* found very high prevalence estimates among blood donors and certain risk groups ranging from 15% to 65% [7].

A recent community-based study from the USA showed a seroprevalence of 3·1% [8], while 4% was

* Author for correspondence: B. Schimmer, M.D., Centre for Infectious Disease Control, National Institute for Public Health and the Environment, PO Box 1, 3720 BA Bilthoven, The Netherlands.
(Email: barbara.schimmer@rivm.nl)

found in a blood donor study in southern France in the late 1980s [9] and 3.6% in Japanese blood donors in the late 1990s [10]. Higher seroprevalences were observed in other western countries: in Northern Ireland, 12.8% in sera collected in 1986–1987 [11], 7.9% in rural Wales in the mid-1990s [12], similar to the 7.5% found in southwestern Germany in 2008–2009 [13]. In northwestern Russia a marked increase in seroprevalence in a healthy population was observed, from 1.1% in 1993 to 11.1% in 2003 [14]. In the UK the seroprevalence was 11.2% in an occupational control cohort in the late 1980s [15]. Mediterranean countries report even higher seroprevalence levels: in Spain, 23.1% in blood donors in Albacete [16], 48.6% in Eastern Cantabria [17], and 15.3% in the Barcelona region [18], while 13.5% was found in north Turkey [19] and 52.7% in Cyprus [20]. A more detailed overview of human seroprevalence studies done in European countries was recently presented in reports by the European Food Safety Authority and the European Centre for Disease Prevention and Control [13, 21]. To understand the baseline epidemiology of Q fever in The Netherlands prior to the epidemics, available serum samples from the general population, collected between February 2006 and June 2007 for evaluation by the Dutch National Immunization Programme [22] were used to obtain a seroprevalence estimate of the general Dutch population just before the recent epidemics. In addition, risk factors for seropositivity were identified.

METHODS AND MATERIALS

Study population and questionnaire data

A large population-based seroprevalence study, called the PIENTER project, was carried out primarily for the evaluation of the Dutch National Immunization Programme. Eight municipalities within each of five geographical Dutch regions (Northeast, Central, Northwest, Southwest and Southeast) were sampled with probabilities proportional to their population sizes (Fig. 1). In addition, there was an oversampling of non-Western migrants in 12 of the above municipalities. Data collection started in February 2006 and was finalized in June 2007. The study design and details of the data collection in the PIENTER project have been published [22]. The participants donated blood and completed a questionnaire, one version for children aged ≤ 14 years, and another version for persons aged ≥ 15 years. The questionnaire covered,




Fig. 1. Selected municipalities in the seroprevalence study. Light grey municipalities are included in the nationwide sample ($n=40$). Dark grey municipalities are low immunization municipalities that are included in the PIENTER project but not in the present study.

among others, data on demographics, health perception and diseases, and activities possibly related to infectious diseases (e.g. travelling, profession, food habits, gardening).

Laboratory analysis

Stored sera of the nationwide sample of the PIENTER project were screened for the presence of *C. burnetii* IgG phase-2-specific antibodies by a commercial enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (Serion ELISA classic, Virion/Serion, Germany). A positive ELISA test was defined according to the manufacturer as a concentration of ≥ 30 U/ml, and a borderline-positive ELISA was defined as a concentration between 20 U/ml and 30 U/ml. We considered ELISA-borderline-positive and ELISA-positive samples as a positive test result. Immunofluorescence assay (IFA) is considered the reference method for diagnostic screening of *C. burnetii* and a lower sensitivity of the ELISA test compared to IFA was anticipated, with a similar specificity [23]. ELISA-borderline-positive and ELISA-positive samples were subsequently confirmed by IFA (Focus Diagnostics,

USA) for IgG phase-1 and phase-2 specific antibodies using a 1:32 and 1:128 dilution. In addition, a random subset of ELISA-negative samples ($n=504$) was screened for IgG phase-1 and phase-2 specific antibodies by IFA at an initial dilution of 1:32 to estimate the proportion of false-negative test results. A positive IFA sample was defined as a sample with an IFA IgG phase-2 titre of ≥ 32 (either or not combined with positive IgG phase 1 of $\geq 1:32$). By extrapolation we additionally estimated the national seroprevalence adjusting for the proportion of false-positive and false-negative results using the IFA as the gold standard.

Statistical analysis

The national sample that was screened by ELISA was used to estimate the seroprevalence of *C. burnetii* IgG antibodies representative of the general population of The Netherlands. Oversampled migrant participants were included to allow studying differences in seroprevalence by country of origin in more detail. Participants from municipalities with low immunization coverage were excluded from the seroprevalence estimation. To produce national estimates, the weighted frequencies were averaged over the 40 participating municipalities in eight different provinces. To avoid missing possible infections, borderline laboratory results were considered positive in the statistical analysis. Weights were calculated proportional to the reference population (Dutch population, 1 January 2007) taking sex, age, ethnicity and degree of urbanization (>2500 vs. <2500 addresses per km^2 in the neighbourhood) into account. We adjusted for the two-stage cluster sampling by taking into account the strata (regions) and clusters (municipalities). The weighted overall and age-, sex- and region-specific seroprevalences were estimated for the Dutch population.

Based on the ELISA results of the complete sample we performed the further risk factor analysis. Univariate odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for selected variables possibly relevant for *C. burnetii* exposure, i.e. geographical region, degree of urbanization, country of birth, religion, educational level, household income, number of persons in the household, consumption of raw meat and unwashed vegetables, being a vegetarian, gardening, playing in a sandbox (only children aged <15 years), keeping a pet (past 5 years), keeping livestock (past 5 years), tick bites (past 5 years), and




Fig. 2. Age-specific weighted seroprevalence of *C. burnetii* IgG antibodies in a representative sample of the Dutch population aged 0–79 years ($n=5654$), PIENTER project, 2006–2007. Prevalence rates per age group were estimated using a linear model with a spline function for age (i.e. second-degree polynomial).

occupational contact with animals (past 5 years). Information from Statistics Netherlands was collected on goat, sheep and cattle density in the participating municipalities. Variables which reached a significance level of $P<0.20$ in the univariate analysis were included in a multivariate logistic regression model. Multivariate analysis was done by a General Logistic Mixed Model with municipality added as a block effect. Selection of model terms was done by backwards elimination to determine independent risk factors for seropositivity using $P<0.05$ as significance level (R, version 2.10; R Foundation, Austria).

RESULTS

Overall seroprevalence

The 5654 stored sera available from the nationwide sample of the PIENTER project were screened for the presence of *C. burnetii* IgG phase 2 by ELISA. Antibodies were detected in sera of 85 study participants, of which 47 had borderline levels, resulting in a weighted rough seroprevalence of 1.5%. Based on ELISA test results only, the weighted seroprevalence was higher in males than in females (1.65% vs. 1.28%). Seropositivity increased with age from 0.48% (95% CI 0.00–0.96) in the 0–4 years age group to 2.30% (95% CI 1.46–3.15) in the 60–79 years age group (Fig. 2). The seroprevalence for those born abroad was slightly higher than for persons born in The Netherlands. Persons with low educational level (i.e. no education or elementary-school level) and those living in a household with a very low monthly income ($\leq \text{€}850$) had the highest seroprevalence.

Table 1. *Weighted* seroprevalence of Coxiella burnetii IgG phase-2 antibodies (Serion ELISA, IgG phase 2) in the Dutch population aged 0–79 years (n = 5654), PIENTER 2 project, The Netherlands, February 2006–June 2007*

	<i>N</i> (<i>n</i> positive)	Seroprevalence (95% CI)
Overall	5654 (85)	1.46 (1.18–1.74)
Sex		
Male	2522 (45)	1.64 (1.21–2.07)
Female	3132 (40)	1.28 (0.90–1.65)
Country of birth		
Other	735 (15)	1.78 (0.98–2.59)
The Netherlands	4833 (68)	1.41 (1.08–1.75)
Age category (yr)		
0–4	571 (4)	0.48 (0.00–0.96)
5–19	1228 (9)	0.71 (0.24–1.19)
20–39	1321 (19)	1.56 (0.92–2.20)
40–59	1266 (23)	1.65 (0.93–2.37)
60–79	1268 (30)	2.30 (1.46–3.15)
Education		
Elementary level	1373 (30)	2.05 (1.33–2.77)
High school	2668 (30)	1.13 (0.68–1.57)
University level	1515 (23)	1.54 (0.88–2.19)
Net income (€/month)		
≤850	354 (10)	2.94 (1.15–4.74)
>850	4126 (62)	1.44 (1.10–1.78)
Region		
Northeast	1328 (19)	1.48 (1.04–1.92)
Central	1025 (18)	1.84 (0.93–2.76)
Northwest	1332 (22)	1.49 (0.86–2.12)
Southwest	998 (13)	1.21 (0.67–1.76)
Southeast	971 (13)	1.23 (0.67–1.78)

CI, Confidence interval.

* Weighted for sex, age, ethnicity and degree of urbanization.

No regional differences in seroprevalence were observed (Table 1).

The 85 ELISA-positive samples were subsequently screened by IFA. Fifteen samples (17.6%) turned out IFA-negative. Of the remaining 70 IFA-positive sera, 13 had a low-level IgG phase-2 titre ranging between 1:32 and <1:128, while 57 sera had a titre of ≥1:128. In the IFA-tested subset of 504 ELISA-negative samples, six samples (1.2%) had low-level IgG phase-2 titres ranging from 1:32 (*n* = 5) to 1:128 (*n* = 1). Correcting the ELISA results with the IFA results, the adjusted overall seroprevalence estimate was 2.4% (70 true positives and 66 false negatives divided by the total number of 5654 study participants).

Determinants of *C. burnetii* seropositivity

Based on ELISA test results only, risk factors significant at the *P* < 0.20 level were increasing age, being male, marital status, not being born in The Netherlands, net income, religion, contact with cats (past 12 months), kept livestock (past 5 years), frequency of eating raw meat, and occupational contact with animals (Table 2). No significant association was found between seropositivity and goat, sheep or cattle density in the 40 municipalities. In the multivariate logistic regression model, seropositivity was found to be associated with keeping ruminants (past 5 years) with or without other farm animals [adjusted OR (aOR) 8.2, 95% CI 3.3–20.8 and aOR 3.8, 95% CI, 1.1–13.1, respectively], being born in Turkey (aOR 5.1, CI 2.1–12.5), and increasing age (aOR 5.4, 95% CI 1.4–20.4 for the 15–39 years age group; aOR 6.0, 95% CI 1.6–22.9 for the 40–59 years age group, and aOR 6.6, 95% CI 1.8–24.0 for the oldest age group of 60–79 years compared to the reference age group of 0–14 years), with borderline significance being observed for occupational contact with animals. Other factors contributing to the multivariate model were low monthly net income (≤€850), and being male, although these did not reach statistical significance (Table 3). In the multivariate analysis, keeping pets seemed to play a protective role (aOR 0.53, 95% CI 0.32–0.87). This variable was included based on the significance of keeping rabbits as a variable in the univariate analysis (*P* = 0.18).

DISCUSSION

The overall Q fever seroprevalence, based on this representative sample of the Dutch population from 2006 to 2007 is relatively low. The overall estimate of 1.5%, and IFA-corrected estimate of 2.4% reflect the seroprevalence in a pre-epidemic period as the tested sera were collected in 2006 and the first half 2007, just before the major Q fever epidemics in 2007–2009. The *a-priori* expected *C. burnetii* IgG phase-2 seroprevalence was estimated to be around 4% based on screening of serum samples of pregnant women outside the epidemic area carried out in 2007 by IFA [24]. For comparison, since the epidemic rise in 2007, seropositivity rates of the general population have probably increased, as shown by a 24% seropositivity rate in the population of the Q fever epicentre of 2007 [3]. In the 1980s, the seroprevalence for *C. burnetii* in blood donors was studied in different regions of

The Netherlands using an IFA developed in-house. Using a low cut-off for positivity in this IFA (screening dilution of 1:16), a high seroprevalence was found, ranging between 15% and 65%, depending on region, sex and age [7]. Unfortunately, no information was available on exact titres measured. It is unknown how current IFAs and ELISAs relate to this previously used in-house IFA, as neither the test nor the sera are available at present. The high seroprevalences found in the 1980s led to the suggestion that *C. burnetii* may have been far more prevalent for a considerable time than the number of notifications suggested, and that before 2007 clinical cases were not detected because of the aspecific presentation of most symptomatic Q fever infections as well as a large proportion of asymptomatic and subclinical infections. Few laboratories had serology for *C. burnetii* in their standard panel for pneumonia patients before national awareness was raised by the Q fever outbreaks.

Several other population studies observed seroprevalences between 2% and 4%, similar to the estimated seroprevalence found in our study [8–10]. However, comparisons of seroprevalence estimates should be made with caution as different study populations, different serological assays and criteria for positivity are used. The latter is especially important in population surveys, while comparisons of assays in The Netherlands for diagnoses of acute cases demonstrate a high concordance of test results. Increasing age, being born in Turkey, keeping ruminants and to a lesser extent occupational contact with animals were identified as independent risk factors for Q fever seropositivity in this study. The increase in seroprevalence with age is consistent with findings from other seroprevalence studies [8, 25]; however, the range of age-specific seroprevalences in our study is smaller. In accord with other studies [8, 11], we showed that young children and adolescents have a very low seroprevalence, which is supported by a very small proportion of children in the notified clinical cases in our routine Q fever surveillance. Keeping ruminants was an independent risk factor in our study as shown also in other studies [8, 11, 25]. Turkey as country of birth was an independent risk factor. In accord with this observation, recent studies in Turkey indicate that Q fever is highly prevalent: prevalence of *C. burnetii* anti-phase-2 IgG was 13.5% in healthy subjects in the west Black Sea region [19] and 32.3% by ELISA in blood donors from Ankara [26].

In southwestern Germany, the seroprevalence showed a linear increase with sheep density in

different municipalities [13]. In our study we did not find an association between goat, sheep and cattle density, and seropositivity in the 40 municipalities, suggesting that the dominant role of the dairy goats in the epidemiology of Q fever in The Netherlands is a relatively recent occurrence. Occupational animal contact was not a strong independent predictor in the multivariate analysis as there was a large overlap with those keeping ruminants. The kind of occupational animal contact was not further specified in the questionnaire which also included contact with non-ruminant species. Livestock farmers, veterinarians, slaughterhouse workers and animal laboratory staff are known occupational risk groups for Q fever, as exemplified by higher seroprevalence levels than the general population [11, 25]. In order to investigate the actual risk for professionals dealing with livestock, separate seroprevalence studies in livestock farmers, veterinarians and persons actively involved in culling activities at infected dairy farms are currently performed in The Netherlands. Although poverty was a risk factor in a seroprevalence study from the USA [8], we cannot fully support this observation as the category with the lowest monthly net income (\leq €850) was not statistically significant in the multivariate model. This is possibly caused by a large proportion in this income group that chose not to disclose their monthly income. Males generally have higher seroprevalence than females, which is often explained by occupational contact. In our study, being male is a possible confounding factor, at least partially explained by occupational exposure to animals. In laboratory surveillance studies, males are more likely to be diagnosed as they more often develop symptoms, as shown in our routine laboratory surveillance. Others suggested that this is explained by sex hormones that may control the host's immune response to a *C. burnetii* infection [27], resulting in gender differences in clinical attack rates. In the case-control study performed during the first epidemic season in 2007 in the main cluster area in the south of The Netherlands we observed a higher proportion of males developing symptoms, while seroprevalence due to the airborne exposure was equally distributed among males and females [3]. It is unclear why keeping pets turned out to be a protective factor. Other studies did not find any association with keeping pets, or in contrast, found pets to be a risk factor, such as in a recent study from Germany where pet rats were surprisingly found as a risk factor (S. Brockmann, unpublished observations). Moreover, several Q fever

Table 2. *Coxiella burnetii* IgG antibodies (%) in study population ($n=5654$) and adjusted* univariate analysis of factors associated with seropositivity to *Coxiella burnetii* PIENTER 2 project, The Netherlands, February 2006–June 2007

Variable	No. (%) of respondents		OR (95% CI)	P
	Seropositive ($n=85$)	Seronegative ($n=5569$)		
Degree of urbanization				0·91
Very urbanized	20 (1·64)	1197 (98·36)	1·34 (0·60–3·28)	
Urbanized	37 (1·47)	2488 (98·53)	1·18 (0·57–2·75)	
Moderately urbanized	10 (1·44)	685 (98·56)	1·18 (0·46–3·13)	
Little urbanized	10 (1·83)	536 (98·17)	1·51 (0·59–4·00)	
Rural	8 (1·19)	663 (98·81)	Reference	
Age category (yr)				<0·01
0–14	7 (0·46)	1516 (99·54)	Reference	
15–39	25 (1·57)	1572 (98·43)	4·02 (1·80–10·22)	
40–59	23 (1·82)	1243 (98·18)	4·62 (2·05–11·81)	
60–79	30 (2·37)	1238 (97·63)	5·87 (2·69–14·73)	
Sex				0·12
Male	45 (1·78)	2477 (98·22)	1·41 (0·92–2·18)	
Female	40 (1·28)	3092 (98·72)	Reference	
Marital status				0·02
Married, registered partnership, living together	52 (1·87)	2733 (98·13)	0·58 (0·31–1·14)	
Not married	18 (2·13)	829 (97·87)	Reference	
Divorced, living apart, widow, widower	7 (1·64)	419 (98·36)	0·48 (0·17–1·29)	
Country of birth				0·02
The Netherlands	68 (1·41)	4765 (98·59)	Reference	
Turkey	6 (6·32)	89 (93·68)	5·23 (1·96–11·72)	
Other country	9 (1·41)	631 (98·59)	0·98 (0·45–1·90)	
Net income (€/month)				0·08
≤850	10 (2·82)	344 (97·18)	2·16 (1·02–4·14)	
>850	62 (1·50)	4064 (98·50)	Reference	
Chose not to answer/ missing	13 (1·11)	1161 (98·89)	0·8 (0·42–1·43)	
Religion				0·08
Protestant Christian	28 (2·15)	1273 (97·85)	1·72 (0·97–3·08)	
Catholic	18 (1·11)	1601 (98·89)	0·88 (0·46–1·65)	
Muslim	11 (2·81)	381 (97·19)	3·23 (1·14–7·98)	
Other religion	5 (1·59)	310 (98·41)	1·38 (0·46–3·43)	
No religion	22 (1·12)	1941 (98·88)	Reference	
Allergies (self-reported)				0·13
No allergies	80 (1·45)	5423 (98·55)	Reference	
Dust allergy	2 (9·09)	20 (90·91)	5·87 (0·90–21·63)	
Contact with cats†				0·09
No contact	47 (1·90)	2428 (98·10)	Reference	
Yes, contact with young cats	0 (0·0)	192 (100·0)	0·00 (0·00–13·49)	
Yes, contact with older cats	25 (1·15)	2141 (98·85)	0·69 (0·42–1·12)	
Yes, both or of unknown age	11 (1·75)	619 (98·25)	1·18 (0·57–2·25)	
Kept pets (past 5 years)				0·21
No	48 (2·00)	2349 (98·00)	Reference	
Yes	35 (1·10)	3147 (98·90)	0·70 (0·44–1·11)	
Kept livestock (past 5 years)				<0·01
No	69 (1·33)	5116 (98·67)	Reference	
Yes, ruminants only	3 (4·62)	62 (95·38)	4·25 (1·00–12·31)	
Yes, ruminants and other farm animals	7 (8·86)	72 (91·14)	8·99 (3·54–19·93)	
Yes, but no ruminants	2 (1·14)	173 (98·86)	1·09 (0·18–3·56)	

Table 2 (cont.)

Variable	No. (%) of respondents		OR (95% CI)	P
	Seropositive (n=85)	Seronegative (n=5569)		
Frequency of eating raw meat				0.13
Does not eat raw meat (including vegetarians)	31 (2.23)	1357 (97.77)	Reference	
Daily/weekly	16 (2.22)	704 (97.78)	1.23 (0.64–2.28)	
Monthly	14 (1.57)	876 (98.43)	0.89 (0.45–1.70)	
Less than monthly	12 (0.96)	1243 (99.04)	0.53 (0.26–1.02)	
Occupational contact				0.01
No contact with animals	63 (1.69)	3657 (98.31)	Reference	
Contact with animals	10 (4.02)	239 (95.98)	2.75 (1.30–5.25)	

OR, Odds ratio; CI, confidence interval.

* Adjusted for sex, age and ethnicity.

† Adjusted for sex and age.

Table 3. Final multivariable model for risk factors associated with seropositivity to *Coxiella burnetii*, PIENTER 2 project, The Netherlands, February 2006–June 2007

Variable	OR (95% CI)	P
Age category (yr)		
0–14	Reference	
15–39	5.41 (1.43–20.40)	0.01
40–59	6.04 (1.59–22.89)	<0.01
60–79	6.62 (1.83–23.99)	<0.01
Sex		
Male	1.42 (0.92–2.21)	0.12
Female	Reference	
Country of birth		
The Netherlands	Reference	
Turkey	5.07 (2.05–12.54)	<0.01
Other country	0.92 (0.44–1.92)	0.83
Net income (€/month)		
≤850	1.62 (0.79–3.33)	0.19
>850	Reference	
Chose not to answer/missing	0.66 (0.35–1.24)	0.20
Kept pets (past 5 years)		
No	Reference	
Yes	0.53 (0.32–0.87)	0.01
Kept livestock (past 5 years)		
No	Reference	
Yes, ruminants only	3.83 (1.12–13.13)	0.03
Yes, ruminants and other farm animals	8.24 (3.26–20.81)	<0.01
Yes, but no ruminants	1.10 (0.26–4.65)	0.89
Occupational contact		
No contact with animals	Reference	
Contact with animals	2.04 (0.93–4.44)	0.07

OR, Odds ratio; CI, confidence interval.

outbreaks in the USA and Canada were associated with parturient cats and dogs [28, 29].

Our study has several limitations as the exposure information collected in the questionnaire was mainly focused on vaccine-preventable infections instead of zoonotic infections. Information on exposures does not necessarily relate to the relevant time period as we do not know at what moment the actual infection with *C. burnetii* occurred in those testing serologically positive. Close contact with animals other than through occupation or ownership and proximity to animal stables or farms could not be studied. Further, the questionnaire did not include information on exact occupation. Possible associations between history of miscarriage or stillbirth in female participants and seropositivity could not be studied, as no information on reproductive history was collected. Our study demonstrated a low prevalence of *C. burnetii* infection in the period 2006–2007, around 1.5% based on ELISA. The Serion IgG ELISA has shown a suboptimal sensitivity of 58% [23], which at least led to an underestimate of the national seroprevalence, which was adjusted in retrospect although based on only a subset of seronegatives. We consider it unlikely that misclassification of serological status was related to the exposure variable and has systematically biased our risk-factor analysis. However, risk factors will be flawed because of dilution of the effect by probable random misclassification. A two-step screening approach, using ELISA as a screening tool and IFA for confirmation, was used in a recent seroprevalence study from the USA [8]. We confirmed that using the same approach, with only the 70 IFA-confirmed ELISA-positive samples in the statistical analysis

instead of 85 ELISA-positive samples, the same risk factors were observed as in the current study (data not shown). A separate risk-factor analysis only based on the subset of IFA-tested samples was not possible due to low seroprevalence.

Further modelling studies are necessary to study the relationship between IFA and ELISA and improve or replace the cut-off for ELISA as a binomial outcome to a probability, which will improve the multivariate analysis of the risk factors, but confidence intervals will remain large. Municipalities in the highest-incidence Q fever areas in 2007–2010 were not part of the study sample. In 2007 a much larger part of Noord-Brabant province was already affected. Several other municipalities in this early-affected province were included in our study sample. However, adjacent municipalities did not show a higher seroprevalence nor was a relationship of seroprevalence with goat density observed.

This study will serve as a baseline for future population-based seroprevalence studies performed after the emergence of Q fever. Prior to the recent Q fever epidemics the overall seroprevalence of *C. burnetii* infection in The Netherlands was relatively low and it was not associated with goat, sheep or cattle density, but merely with keeping ruminants or occupational contact with animals. This supports the hypothesis that The Netherlands has been confronted with a newly emerging Q fever problem in the general population since the spring of 2007. Before the start of the epidemics, high-risk groups for Q fever were individuals with animal contact, including occupational exposure, and Turkish immigrants, probably infected in their home country. Further modelling studies are needed to study the relationship between IFA and ELISA in order to improve comparison between seroprevalence studies.

ACKNOWLEDGEMENTS

We thank the participating municipal health services and the municipalities involved in this study, the PIENTER project team and all participants for their contribution. We also thank Wim van der Hoek and Tineke Herremans (Cib/RIVM) for their useful comments on the manuscript.

DECLARATION OF INTEREST

None.

REFERENCES

1. Schimmer B, *et al.* Large ongoing Q fever outbreak in the south of The Netherlands, 2008. *Eurosurveillance* 2008; **13**: pii = 18939 (<http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18939>).
2. Schimmer B, *et al.* Sustained intensive transmission of Q fever in the south of the Netherlands, 2009. *Eurosurveillance* 2009; **14**: pii = 19210 (<http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19210>).
3. Karagiannis I, *et al.* Investigation of a Q fever outbreak in a rural area of The Netherlands. *Epidemiology and Infection* 2009; **137**: 1283–1294.
4. Schimmer B, *et al.* The use of a geographic information system to identify a dairy goat farm as the most likely source of an urban Q-fever outbreak. *BMC Infectious Diseases* 2010; **10**: 69.
5. van der Hoek W, *et al.* Q fever in the Netherlands: an update on the epidemiology and control measures. *Eurosurveillance* 2010; **15**: pii = 19520 (<http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19520>).
6. van den Wijngaard CC, *et al.* In search of hidden Q-fever outbreaks: linking syndromic hospital clusters to infected goat farms. *Epidemiology and Infection* 2011; **139**: 19–26.
7. Richardus JH, *et al.* Q fever in the Netherlands: a sero-epidemiological survey among human population groups from 1968 to 1983. *Epidemiology and Infection* 1987; **98**: 211–219.
8. Anderson AD, *et al.* Seroprevalence of Q fever in the United States, 2003–2004. *American Journal of Tropical Medicine and Hygiene* 2009; **81**: 691–694.
9. Tissot DH, *et al.* Epidemiologic features and clinical presentation of acute Q fever in hospitalized patients: 323 French cases. *American Journal of Medicine* 1992; **93**: 427–434.
10. Abe T, *et al.* A seroepidemiological study of the risks of Q fever infection in Japanese veterinarians. *European Journal of Epidemiology* 2001; **17**: 1029–1032.
11. McCaughey C, *et al.* Human seroprevalence to *Coxiella burnetii* (Q fever) in Northern Ireland. *Zoonoses and Public Health* 2008; **55**: 189–194.
12. Davies TR, *et al.* Prevalence of Q fever in a rural practice. *Journal of Public Health Medicine* 1997; **19**: 324–327.
13. European Centre for Disease Prevention and Control. Technical report: risk assessment on Q fever. Stockholm, Sweden: ECDC, 2010, pp. 40.
14. Tokarevich NK, *et al.* Anthropogenic effects on changing Q fever epidemiology in Russia. *Annals of the New York Academy of Sciences* 2006; **1078**: 120–123.
15. Thomas DR, *et al.* The risk of acquiring Q fever on farms: a seroepidemiological study. *Occupational and Environmental Medicine* 1995; **52**: 644–647.
16. Bartolome J, *et al.* Seroepidemiology of *Coxiella burnetii* infection among blood donors in Albacete. *Enfermedades Infecciosas y Microbiología Clínica* 2007; **25**: 382–386.

17. **Pascual-Velasco F, et al.** High seroprevalence of *Coxiella burnetii* infection in Eastern Cantabria (Spain). *International Journal of Epidemiology* 1998; **27**: 142–145.
18. **Cardenosa N, et al.** Short report: seroprevalence of human infection by *Coxiella burnetii* in Barcelona (northeast of Spain). *American Journal of Tropical Medicine and Hygiene* 2006; **75**: 33–35.
19. **Gozalan A, et al.** Seroprevalence of Q fever in a district located in the west Black Sea region of Turkey. *European Journal of Clinical Microbiology and Infectious Diseases* 2010; **29**: 465–469.
20. **Psaroulaki A, et al.** Epidemiological study of Q fever in humans, ruminant animals, and ticks in Cyprus using a geographical information system. *European Journal of Clinical Microbiology & Infectious Diseases* 2006; **25**: 576–586.
21. **European Food Safety Authority.** Scientific opinion on Q fever. *EFSA Journal* 2010; **8**: 1–114.
22. **van der Klis FR, et al.** Second national serum bank for population-based seroprevalence studies in the Netherlands. *Netherlands Journal of Medicine* 2009; **67**: 301–308.
23. **Blaauw GJ, et al.** The application of an enzyme-linked immunosorbent assay or an immunofluorescent assay test leads to different estimates of seroprevalence of *Coxiella burnetii* in the population. *Epidemiology and Infection* 2011. doi:10.1017/S0950268811000021.
24. **Meekelenkamp JC, et al.** Seroprevalence of *Coxiella burnetii* in pregnant women in the province of Noord-Brabant in 2007. *Infectieziekten Bulletin* 2009; **20**: 57–61.
25. **Whitney EA, et al.** Seroepidemiologic and occupational risk survey for *Coxiella burnetii* antibodies among US veterinarians. *Clinical Infectious Diseases* 2009; **48**: 550–557.
26. **Kilic S, et al.** Prevalence of *Coxiella burnetii* antibodies in blood donors in Ankara, Central Anatolia, Turkey. *New Microbiologica* 2008; **31**: 527–534.
27. **Leone M, et al.** Effect of sex on *Coxiella burnetii* infection: protective role of 17betaestradiol. *Journal of Infectious Diseases* 2004; **189**: 339–345.
28. **Pinsky RL, et al.** An outbreak of cat-associated Q fever in the United States. *Journal of Infectious Diseases* 1991; **164**: 202–204.
29. **Buhariwalla F, Cann B, Marrie TJ.** A dog-related outbreak of Q fever. *Clinical Infectious Diseases* 1996; **23**: 753–755.